Chemed (NYSE:CHE – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $5.47 earnings per share for the quarter, missing analysts’ consensus estimates of $5.59 by ($0.12), Briefing.com reports. The business had revenue of $595.88 million during the quarter, compared to analyst estimates of $599.20 million. Chemed had a return on equity of 29.90% and a net margin of 12.88%. The firm’s revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.71 EPS. Chemed updated its FY24 guidance to $23.55-23.80 EPS and its FY 2024 guidance to 23.550-23.800 EPS.
Chemed Trading Up 1.9 %
CHE traded up $10.12 during midday trading on Friday, hitting $551.09. 39,669 shares of the company traded hands, compared to its average volume of 85,021. The company has a market capitalization of $8.34 billion, a price-to-earnings ratio of 29.50, a PEG ratio of 2.25 and a beta of 0.43. Chemed has a 52-week low of $492.84 and a 52-week high of $654.62. The business has a 50 day simple moving average of $543.57 and a two-hundred day simple moving average of $583.29.
Chemed Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Thursday, May 30th. Chemed’s payout ratio is 8.61%.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Chemed
Insider Buying and Selling at Chemed
In other Chemed news, Director Patrick P. Grace sold 284 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $540.98, for a total transaction of $153,638.32. Following the transaction, the director now directly owns 3,270 shares of the company’s stock, valued at $1,769,004.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Kevin J. Mcnamara sold 4,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $567.54, for a total value of $2,270,160.00. Following the transaction, the chief executive officer now directly owns 108,549 shares of the company’s stock, valued at $61,605,899.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Patrick P. Grace sold 284 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total transaction of $153,638.32. Following the completion of the transaction, the director now directly owns 3,270 shares in the company, valued at $1,769,004.60. The disclosure for this sale can be found here. Insiders have sold a total of 5,784 shares of company stock valued at $3,240,053 over the last ninety days. Corporate insiders own 3.32% of the company’s stock.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Read More
- Five stocks we like better than Chemed
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Are Dividend Champions? How to Invest in the Champions
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Using the MarketBeat Dividend Yield Calculator
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.